Medical Department, Aqma Italia S.p.A., 20123 Milan, Italy.
Medical Department, Merqurio Pharma S.r.l., 80138 Naples, Italy.
Medicina (Kaunas). 2020 Oct 17;56(10):544. doi: 10.3390/medicina56100544.
Non-Alcoholic Fatty Liver Disease (NAFLD) is an emerging cause of hepatopathy that is showing an increasing trend and where the recommendations of lifestyle modification are often not sufficient. The aim of this study is to evaluate the efficacy and tolerability profile of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato) by analyzing liver enzymes, along with the lipidic profile, as markers of liver function, and ultrasound results in NAFLD patients. This study enrolled 81 patients with mild to severe NAFLD, divided into two groups: Group A (N = 41) received two capsules a day of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato), and Group B (N = 40) received only recommendations for lifestyle modification including hypocaloric diet, physical exercise and encouragement for weight loss. Patients have been evaluated at three timepoints: baseline (T0), after 45 days of treatment (T1) and after 90 days of treatment (T2), by collecting blood parameters of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) and the lipid blood profile. Ultrasonographic results have been analyzed at T0 and T2, along with the tolerability profile and side effects, registered at time T2. The administration of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato) was effective since it showed a significant reduction of the evaluated parameters of ALT, AST, ALP and GGT, a significant improvement of lipid parameters, evaluated as markers of liver function, and improvements of ultrasonographic results. The use of this formulation at the dosage of two capsules a day has been well tolerated and no adverse events have been reported during study period of three months. The administration of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato) was effective and well tolerated in the improvement of hepatic function of NAFLD patients.
非酒精性脂肪性肝病(NAFLD)是一种新兴的肝病病因,其发病率呈上升趋势,而生活方式改变的建议往往并不足够。本研究旨在评估水飞蓟素、维生素 C、维生素 E、辅酶 Q10 和硒代蛋氨酸(Medronys epato)联合治疗对 NAFLD 患者肝功能的疗效和耐受性,通过分析肝酶以及血脂谱作为肝功能标志物,以及超声结果。 这项研究共纳入 81 例轻至重度 NAFLD 患者,分为两组:A 组(N = 41)每天服用 2 粒水飞蓟素、维生素 C、维生素 E、辅酶 Q10 和硒代蛋氨酸(Medronys epato),B 组(N = 40)仅接受生活方式改变的建议,包括低热量饮食、体育锻炼和鼓励减肥。患者在三个时间点进行评估:基线(T0)、治疗 45 天后(T1)和治疗 90 天后(T2),通过收集丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)、γ-谷氨酰转移酶(GGT)和血脂参数。在 T0 和 T2 时分析超声结果,并在 T2 时分析耐受性和副作用。 水飞蓟素、维生素 C、维生素 E、辅酶 Q10 和硒代蛋氨酸(Medronys epato)联合治疗有效,因为它显著降低了 ALT、AST、ALP 和 GGT 的评估参数,显著改善了肝功能的脂质参数,以及超声结果的改善。每天服用 2 粒该配方的剂量耐受性良好,在三个月的研究期间未报告不良反应。 水飞蓟素、维生素 C、维生素 E、辅酶 Q10 和硒代蛋氨酸(Medronys epato)联合治疗在改善 NAFLD 患者肝功能方面有效且耐受性良好。